Connect Biopharma Holdings Stock Price Prediction
| CNTB Stock | USD 1.54 0.02 1.32% |
Oversold Vs Overbought
66
Oversold | Overbought |
Connect Biopharma stock price prediction is an act of determining the future value of Connect Biopharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Connect Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Connect Biopharma and does not consider all of the tangible or intangible factors available from Connect Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with Connect Biopharma Holdings, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Connect Biopharma's stock price prediction:EPS Estimate Current Year (0.82) | EPS Estimate Next Year (0.54) | Wall Street Target Price 7 |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Connect Biopharma based on different types of headlines from major news networks to social media. The Connect stock price prediction module provides an analysis of price elasticity to changes in media outlook on Connect Biopharma over a specific investment horizon. Using Connect Biopharma hype-based prediction, you can estimate the value of Connect Biopharma Holdings from the perspective of Connect Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Connect Biopharma using Connect Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Connect using crowd psychology based on the activity and movement of Connect Biopharma's stock price.
Connect Biopharma Implied Volatility | 0.0 |
Connect Biopharma's implied volatility exposes the market's sentiment of Connect Biopharma Holdings stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Connect Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Connect Biopharma stock will not fluctuate a lot when Connect Biopharma's options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Connect Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Connect Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Connect because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Connect Biopharma after-hype prediction price | USD 1.47 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Connect |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Connect Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Connect Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Connect Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Connect Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Connect Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Connect Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Connect Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Connect Biopharma's historical news coverage. Connect Biopharma's after-hype downside and upside margins for the prediction period are 0.07 and 10.49, respectively. We have considered Connect Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Connect Biopharma is dangerous at this time. Analysis and calculation of next after-hype price of Connect Biopharma is based on 3 months time horizon.
Connect Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Connect Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Connect Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Connect Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.81 | 9.02 | 0.05 | 0.03 | 6 Events / Month | 6 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.54 | 1.47 | 3.29 |
|
Connect Biopharma Hype Timeline
Connect Biopharma is currently traded for 1.54. The entity has historical hype elasticity of -0.05, and average elasticity to hype of competition of 0.03. Connect is anticipated to decline in value after the next headline, with the price expected to drop to 1.47. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -3.29%, whereas the daily expected return is currently at 0.81%. The volatility of related hype on Connect Biopharma is about 27753.85%, with the expected price after the next announcement by competition of 1.57. About 41.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. Connect Biopharma recorded a loss per share of 1.53. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 6 days. Check out Connect Biopharma Basic Forecasting Models to cross-verify your projections.Connect Biopharma Related Hype Analysis
Having access to credible news sources related to Connect Biopharma's direct competition is more important than ever and may enhance your ability to predict Connect Biopharma's future price movements. Getting to know how Connect Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Connect Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ASMB | Assembly Biosciences | (0.32) | 7 per month | 3.24 | 0.14 | 6.39 | (4.63) | 19.82 | |
| NLTX | Neoleukin Therapeutics | (0.12) | 2 per month | 0.00 | (0.04) | 6.67 | (5.67) | 15.97 | |
| TIL | Instil Bio | (0.28) | 8 per month | 1.73 | 0.13 | 6.43 | (3.60) | 25.51 | |
| CTMX | CytomX Therapeutics | 0.01 | 9 per month | 3.83 | 0.02 | 8.16 | (5.80) | 50.71 | |
| ACHL | Achilles Therapeutics PLC | (0.02) | 10 per month | 5.99 | (0) | 9.56 | (9.02) | 38.89 | |
| NXTC | NextCure | 0.15 | 4 per month | 4.65 | 0.1 | 8.13 | (7.93) | 32.17 | |
| NUVB | Nuvation Bio | 0.70 | 9 per month | 4.03 | 0.12 | 16.67 | (6.50) | 46.16 | |
| OVID | Ovid Therapeutics | 0.14 | 9 per month | 2.89 | 0.02 | 4.92 | (4.39) | 15.42 |
Connect Biopharma Additional Predictive Modules
Most predictive techniques to examine Connect price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Connect using various technical indicators. When you analyze Connect charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Connect Biopharma Predictive Indicators
The successful prediction of Connect Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Connect Biopharma Holdings, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Connect Biopharma based on analysis of Connect Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Connect Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Connect Biopharma's related companies. | 2022 | 2023 | 2024 (projected) | Net Debt To EBITDA | 0.72 | 0.83 | 1.41 | Intangibles To Total Assets | 0.0182 | 4.92E-4 | 4.68E-4 |
Story Coverage note for Connect Biopharma
The number of cover stories for Connect Biopharma depends on current market conditions and Connect Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Connect Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Connect Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Connect Biopharma Short Properties
Connect Biopharma's future price predictability will typically decrease when Connect Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Connect Biopharma Holdings often depends not only on the future outlook of the potential Connect Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Connect Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 55.1 M | |
| Cash And Short Term Investments | 118.7 M |
Check out Connect Biopharma Basic Forecasting Models to cross-verify your projections. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Connect Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.